Fidelity Investments’s Telix Pharmaceuticals TLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.04M Sell
550,548
-10,658
-2% -$121K ﹤0.01% 2375
2026
Q2
$6.47M Sell
561,206
-3,551
-0.6% -$36.2K ﹤0.01% 2326
2026
Q1
$5.4M Buy
564,757
+441,187
+357% +$3.36M ﹤0.01% 2278
2025
Q4
$926K Buy
123,570
+5,091
+4% +$49K ﹤0.01% 2873
2025
Q3
$1.13M Buy
118,479
+76,388
+181% +$936K ﹤0.01% 2753
2025
Q2
$681K Buy
+42,091
New +$707K ﹤0.01% 2861

Other funds holding TLX

Fidelity Investments's TLX Position: Q3 2026 in Review

Fidelity Investments reduced its Telix Pharmaceuticals (TLX) stake by 1.9% in Q3 2026, selling an estimated $121K and leaving 550,548 shares worth $6.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Fidelity Investments first reported a position in TLX in Q2 2025 and has held it in 6 quarters since. The position peaked at $6.47M in Q2 2026. 74 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

  • Fidelity Investments held 550,548 shares of Telix Pharmaceuticals worth $6.04M as of Q3 2026.
  • Fidelity Investments sold 10,658 Telix Pharmaceuticals shares in Q3 2026, an estimated $121K.
  • Telix Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #2375 holding.
  • Fidelity Investments first reported a position in Telix Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Fidelity Investments's Telix Pharmaceuticals position peaked at $6.47M in Q2 2026.
  • 74 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.